E
NYMX

Ergoteles’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Ergoteles’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-101,332
Closed -$132K – 1740
2021
Q4 		$132K Sell
101,332
-83,601
-45% -$133K 0.01% 1114
2021
Q3 		$381K Sell
184,933
-1,277
-0.7% -$2.26K 0.01% 697
2021
Q2 		$294K Buy
+186,210
New +$345K 0.01% 1077

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
DDC
DF Dent & Co Baltimore, Maryland $5.27B AUM 7.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Ergoteles's NYMX Position: Q1 2022 in Review

Ergoteles sold out of Nymox Pharmaceutical Corp (NYMX) in Q1 2022, closing a stake of 101,332 shares — an estimated $132K sold.

Ergoteles first reported a position in NYMX in Q2 2021 and held it in 3 quarters. The position peaked at $381K in Q3 2021. 40 funds tracked by Wall St. Rank hold NYMX as of Q1 2022.

  • Ergoteles reported no remaining Nymox Pharmaceutical Corp position as of Q1 2022 after selling out during the quarter.
  • Ergoteles sold 101,332 Nymox Pharmaceutical Corp shares in Q1 2022, an estimated $132K.
  • Ergoteles first reported a position in Nymox Pharmaceutical Corp in Q2 2021 and held it in 3 quarters.
  • Ergoteles's Nymox Pharmaceutical Corp position peaked at $381K in Q3 2021.
  • 40 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q1 2022.

Based on Ergoteles's 13F filing for Q1 2022, filed 13 May 2022.